Lineage Cell Therapeutics Inc LCTX

$0.82 +0.02 (2.60%)

Valuation

Market cap
231,309,000
Revenue TTM
$14,560,000
Net income TTM
$-63,530,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-436.33%
Debt to equity
0.00

Trading

Volume
6,784,315
Avg volume
1,726,316
Day's range
$0.77 – $0.88
Shares out
252,907,000
Stochastic %K
7%
Beta
1.68
Analysts
Strong Buy
Price target
$5.14

Price

Company profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte...

Show more

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Industry
Biotechnology
Sector
Healthcare
Phone
442 287 8990
Website
https://www.lineagecell.com
Address
2173 Salk Avenue, Suite 200, Carlsbad, United States

Latest news

Stocktwits

jackedmund99 Nov 17, 8:55 PM 0 replies
jackedmund99 Nov 17, 8:53 PM
$SLS $SLS two years ago the stock was $.97 - now the science comes out sbd boom - so look at another stock under a buck check out $LCTX do your research. They’re in a very similar phase in their career with getting approval from the feds strong partners in Hoffman-Roche Genentech even stronger, major shareholder controlling close to 60% of the stock.
0 replies
jackedmund99 Nov 17, 8:34 PM
$SLS two years ago the stock was $.97 wanna buy another stock under a buck check out $LCTX do your research. They’re in a very similar phase in their career with getting approval from the feds strong partners in Hoffman-Roche Genentech even stronger, major shareholder controlling close to 60% of the stock.
0 replies
jackedmund99 Nov 17, 8:18 PM
$LCTX look at $SLS Look what happens when results prove teck and they only cut deaths down by 41% now it’s got a multi billion dollar market cap. This is what happens to biotech. This is why we’re all involved in LCTX if we’re right, it’s a 10 2O 30 bagger who the hell knows but it’s certainly worth more than $.80 right now
2 replies
dannyschell Nov 17, 8:15 PM
$LCTX not expecting any decent news until late 27.
0 replies
MR_PINKS Nov 17, 7:36 PM
$LCTX Alpha Dog? This one's for you! Go get you some of this crap! Science has raised a $400 million Series D financing with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech, among others. This brings the total capital raised since our founding in 2021 to more than $900 million. This round comes a few months after our European commercial launch of PRIMA, the first brain-computer interface to be CE marked to restore form vision—the ability to read letters, numbers, and words—for patients blinded by certain types of late-stage macular degeneration. We’ll use the new capital to accelerate PRIMA’s availability across Europe and to prepare for its launch in the United States, where we’re pursuing FDA approval through the Humanitarian Device Exemption pathway.
0 replies
sfoblader Nov 17, 7:15 PM
$LCTX If Lineage Cell Therapeutics (LCTX) proves it can mass-produce islet cells cheaply, it solves a major bottleneck in Type 1 Diabetes (T1D) care and becomes a prime licensing target across three partner tiers: • Tier 1: Legacy Diabetes Giants (Defending Market Share). Novo Nordisk, Eli Lilly, and Sanofi dominate insulin sales. Licensing LCTX's cell supply lets them pair mass production with their delivery or immune-delaying tools to protect their franchises. • Tier 2: Cell Therapy Leaders (Solving Manufacturing Bottlenecks). Vertex, Sana Biotechnology, and CRISPR Therapeutics hold strong clinical candidates. They would tap LCTX's 5D platform to cut commercial production costs and scale immune-evading cells. • Tier 3: Existing Allies & New Entrants (Plug-and-Play Expansion). Current partner Roche/Genentech already trusts LCTX's manufacturing and could easily expand into T1D. Meanwhile, cash-rich pharmas like AstraZeneca, Merck, or J&J gain turnkey entry into regenerative medicine.
1 replies
JohnPDaly Nov 17, 5:56 PM
$LCTX https://x.com/lineagecell/status/2122743834106851370?a=EeZxdE7bfOl-JkhrI6M&s=12
0 replies